AstraZeneca

Christer Betsholtz appointed new Head of Karolinska Institutet and AstraZeneca’s Integrated Cardio Metabolic Centre

15 Juni 2016 08:00

Karolinska Institutet and AstraZeneca have today announced the appointment of Professor Christer Betsholtz as the new Director of their Integrated Cardio Metabolic Centre (ICMC) in Stockholm, Sweden.
Christer Betsholtz,PhD, is a leading scientific authority in the field of vascular biology with more than 300 publications. He is currently professor with tenure at Uppsala University and Karolinsk

AstraZeneca ingår kommersialiseringsavtal med Aspen för produktportföljen inom anestetika

9 Juni 2016 08:06

Avtalet utökar den kommersiella räckvidden för anestetika och stödjer bolagets tydliga fokus på innovativa, nya läkemedel inom tre huvudterapiområden

LYNPARZA (OLAPARIB): LATEST DATA SUGGEST POTENTIAL OVERALL SURVIVAL ADVANTAGE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER

7 Juni 2016 08:05

AstraZeneca presented (at ASCO in the evening of June 5) results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial.

TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER

6 Juni 2016 17:00

Osimertinib data reported at ASCO 2016 demonstrated improved neurological function in patients with EGFRm NSCLC and leptomeningeal disease Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier

AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America

2 Juni 2016 08:01

Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout

Positive CHMP opinion in EU for saxa/dapa (saxagliptin and dapagliflozin) for adults with type-2 diabetes

27 Maj 2016 14:18

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. .

AstraZeneca’s Faslodex met primary endpoint in first-line treatment of advanced breast cancer

27 Maj 2016 08:06

AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer

AstraZeneca receives Complete Response Letter from US FDA for sodium zirconium cyclosilicate (ZS-9) for oral suspension for treatment of hyperkalaemia

27 Maj 2016 08:03

AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca

STUDIE VISAR ATT ”MOBIL-APP” FÖRBÄTTRADE FÖLJSAMHET TILL BEHANDLING EFTER HJÄRTINFARKT

25 Maj 2016 14:31

Resultaten från den svenska SUPPORT-studien, som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt med hjälp av en mobiltelefonapplikation, publiceras nu i American Heart Journal. Studien visar att de patienter som fick ett interaktivt patientverktyg i form av en ”mobil-app” i högre grad tog sitt blodproppshämmande läkemedel ticagrelor enligt läkarens ordination.

AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016 - Leadership in DNA damage response therapies

19 Maj 2016 08:06

73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour types Continued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation, and new data in first-line NSCLC

AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer

18 Maj 2016 08:03

AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein.

AstraZeneca tillkännager positiva resultat från fas III-studier med benralizumab vid behandling av svår astma

17 Maj 2016 08:02

Benralizumab är AstraZenecas första biologiska läkemedel för sjukdomar i andningsvägarna som slutfört studier i fas III

Nyhetsarkiv